Are dacomitinib and dacomitinib the same?

Dacomitinib (Dacomitinib) and dacomitinib are the same drug, but slightly different in naming. Their names are only used in different countries or regions and have the same chemical structure and similar pharmacological effects. Other common names for dacomitinib include Dacomitinib, Feixintuo, Vizimpro, and Dozerun.

Dacomitinib is an antineoplastic agent also known as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. First-line treatment of metastatic non-small cell lung cancer for patients with tumors that are positive for EGFR exon 19 deletion (del19) or exon 21 (L858R) substitution mutations as detected by U.S. Food and Drug Administration (FDA) -approved diagnostic tests (such as EGFR RGQ therascreen PCR kit, Cobas EGFR mutation test v2). Dacomitinibis one of several generally recommended treatments for patients with previously untreated non-small cell lung cancer with EGFR activating mutations.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).